Dorzolamide
- Generic Name
- Dorzolamide
- Brand Names
- Cosopt, Trusopt
- Drug Type
- Small Molecule
- Chemical Formula
- C10H16N2O4S3
- CAS Number
- 120279-96-1
- Unique Ingredient Identifier
- 9JDX055TW1
- Background
Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. Unlike oral CA inhibitors, dorzo...
- Indication
Dorzolamide is indicated for the management of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It can also be used in combination with timolol for the same indication in patients who are insufficiently responsive to ophthalmic beta-blockers.
...
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Ocular Hypertension
- Associated Therapies
- -
Pupillary Response After Glaucoma Medication
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Glostrup University Hospital, Copenhagen
- Target Recruit Count
- 21
- Registration Number
- NCT02522039
- Locations
- 🇩🇰
Glostrup University Hospital, Glostrup, Denmark
Stop Retinal Ganglion Cell Dysfunction Study
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 500
- Registration Number
- NCT02390284
- Locations
- 🇺🇸
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States
1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT
- Conditions
- Interventions
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 6
- Registration Number
- NCT00767481
Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 200
- Registration Number
- NCT00761995
- Locations
- 🇮🇳
Alcon Laboratories, India, Bangalore, India
Pharmacological Intervention in Diabetic Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2010-12-29
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 87
- Registration Number
- NCT00619034
- Locations
- 🇩🇰
Department of Ophthalmology, Aarhus, Denmark
Circadian Rhythms of Aqueous Humor Dynamics in Humans
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 30
- Registration Number
- NCT00572936
- Locations
- 🇺🇸
University of Nebraska Medical Center, Department of Ophthalmolgy and Visual Sciences, Omaha, Nebraska, United States
Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 46
- Registration Number
- NCT00471068
- Locations
- 🇵🇹
Coimbra, Coimbra, Portugal
Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.
- Conditions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2007-03-01
- Lead Sponsor
- Advanced Glaucoma Specialists
- Target Recruit Count
- 30
- Registration Number
- NCT00440336
- Locations
- 🇺🇸
Advanced Glaucoma Specialist, Reading, Massachusetts, United States
12-Month Stability of Diurnal IOP Control on Cosopt
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 10
- Registration Number
- NCT00379834
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2021-02-18
- Target Recruit Count
- 238
- Registration Number
- NCT00140049
- Locations
- 🇸🇪
Pfizer Investigational Site, örebro, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.